Mateon Therapeutics, Inc.
MATN
MATN was delisted on the 7th of December, 2016.
1 hedge funds and large institutions have $22K invested in Mateon Therapeutics, Inc. in 2021 Q1 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.
69% more capital invested
Capital invested by funds: $13K → $22K (+$9K)
0% more funds holding
Funds holding: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IA
IFP Advisors
Tampa,
Florida
|
+$83 |
Top Sellers
MATN Hedge Fund Activity: Q1 2021 in Review
1 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Mateon Therapeutics, Inc. (MATN) for Q1 2021, worth a combined $22K — up 69% from $13K a quarter earlier.
Fund positioning in MATN was balanced in Q1 2021: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was IFP Advisors, adding an estimated $83.
- 1 institutional investor held Mateon Therapeutics, Inc. (MATN) as of Q1 2021, unchanged from Q4 2020.
- Funds reported $22K of Mateon Therapeutics, Inc. stock for Q1 2021, up 69% quarter-over-quarter.
- 0 funds opened new Mateon Therapeutics, Inc. positions in Q1 2021 and 0 closed out.
- The largest Mateon Therapeutics, Inc. buyer in Q1 2021 was IFP Advisors, an estimated $83 added.
Based on aggregated 13F filings for Q1 2021.